Members of the Bowel & Cancer Research grants committee make a vital contribution to our work. In essence, we couldn't do what we do without them.
They are a voluntary group of experts who give their time to assessing and monitoring the research that we invest in according to our published criteria.
They represent a broad range of expertise from within digestive diseases and other disease areas, including stem cell and molecular biology, motility and neuromodulation, histopathology, immunology, nanotechnology and medical statistics.
Their decision making is supported by lay representatives who bring a unique perspective to considerations.
Diana is a Medical Consultant (Pharmaceutical) with Sage Associates Ltd.
Nadine is a statistician within the Pragmatic Clinical Trials Unit at Barts and the London School of Medicine and Dentistry.
After completing a Diploma in Biomathematics (University Zittau/Görlitz, Germany, 2008) and an MSc in Medical Statistics (London School of Hygiene and Tropical Medicine, 2009), Nadine spent six months as a statistician at the Medical Research Council GPRF Unit, London, working on a large primary care database in the area of insomnia, cholesterol and depression in pregnancy. She also taught a course on handling missing data for members of the MRC as well as external personel. She joined the Centre for Health Sciences in January 2011.
Mohammad is Professor of Pathology in the Faculty of Medical and Health Sciences at the University of Nottingham.
Simon is the Leader of the Gut Microbes and Health Group at the Quadram Institute.
Upon completing postgraduate work at the Medical Research Council’s Clinical Research Centre in Harrow, Simon “emigrated” to the USA to take up a postdoctoral position at New York University School of Medicine, and then at Yale University as a Howard Hughes Fellow in the Immunobiology Group at Yale University. While at Yale he gained an interest in gamma-delta (γδ) T cells working closely with Adrian Hayday on molecular genetics and then with Professor Peter Doherty to establish their role in (viral) infectious disease.
After Yale Simon took up a faculty position at the University of Pennsylvania in Philadelphia where he developed a research interest in mucosal and GI-tract immunology, performing studies in germfree mice with Professor John Cebra that helped establish the role of gut microbes in the aetiology of inflammatory bowel disease (IBD).
After 15 years in the USA, he returned to the UK to take up the Chair in Molecular Immunology at the University of Leeds where he established a new research programme on commensal gut bacteria and Bacteroides genetics leading to the development of a Bacteroides drug delivery platform that is being used for developing new interventions for IBD and for mucosal vaccination.
In 2008 he was recruited by UEA and IFR to develop a gut research programme, taking up the Chair of Mucosal Immunology at UEA-MED and the position of Head of the Gut Biology Research Programme at IFR, which later became part of the Gut Health and Food Safety (GHFS) Programme. GHFS research covers a broad area of gut biology including epithelial cell physiology, mucus and glycobiology, mucosal immunology, commensal microbiology, foodborne bacterial pathogens, and mathematical modelling and bioinformatics. The success of this programme has led to the establishment of the Gut Microbes and Health research programme that is integral to the research agenda of The Quadram Institute.
Simon is a CRUK Clinician Scientist and Honorary Consultant Gastroenterologist in the Nuffield Department of Medicine at the University of Oxford.
Adult gastrointestinal stem cells are the targets of carcinogenic gene mutations and are believed to be the cells of origin of luminal gastrointestinal cancers. Simon's team's published work has examined the clonality and genetic mutation burden of pre-neoplastic gastrointestinal disease. Their current research focuses on the homeostatic cell-signaling pathways that control intestinal stem cells and the dysregulation of these pathways in carcinogenesis. The wnt pathway is the best characterised system and promotes the maintenance and proliferation of stem cells, however other signaling pathways such as the Bone Morphogenetic Protein (BMP) and Notch pathway cross-talk and interact with wnt signaling. Recent work from their laboratory on hereditary polyposis syndromes and genome-wide association studies in sporadic colorectal cancer patients has implicated the BMP pathway’s involvement in predisposition to colorectal cancer.
Philip is a Clinical Research Fellow at the Wingate Institute for Neurogastroenterology.
Philip studied at University College London where he obtained a BSc. in Pharmacology and a medical degree, graduating in 2003. Following this he continued his basic medical training on the Barts and The London medical SHO rotation, during which time he gained membership of the Royal College of Physicians. He entered gastroenterology and general internal medicine specialist training in London in 2007. He took up mya post at the Wingate Institute for Neurogastroenterology in June 2010.
Marilena is the Deputy Director of the Division of Surgery and Interventional Science (SIS) at UCL and Head of the SIS Department at the Royal Free campus.
Marilena Loizidou is Deputy Director of the Division of Surgery and Interventional Science (SIS) at UCL; and Head of the SIS Department at the Royal Free Campus.
After her undergraduate training in Biochemistry (McMasters University, Canada), she moved to the University of Southampton where she obtained her PhD in Solid Tumour Biology and Pharmacology and became lead clinical scientist at the University of Southampton/NHS. She moved to UCL to the academic department of Surgery, and became Head of Department in 2013.
Marilena uses nanotechnology tools in her cancer pharmacology research. Her main focus has been in the field of novel imaging and targeted therapeutics in solid tumours, mainly colorectal cancer, with a focus on the role of the fibrotic cancer stroma. ML co-invented tumouroids, 3D in vitro cultures of cancer which mimic the composition and architecture of solid tumours. Tumouroids are being developed as platforms for therapeutics and for stratified medicine.
Marilena is co-Founder and Director of the MSc in Nanotechnology and Regenerative Medicine and the MSc in Surgical and Interventional Sciences.
David is the Deputy Director of Research at the Blizard Institute.
After graduating from Sheffield University, David joined the Imperial Cancer Research Fund as a Scientific Officer where he completed a PhD on the “Genetics of familial breast cancer”. His PhD involved genetic studies to identify the two breast cancer genes, BRCA1 and BRCA2 and their importance in familial and sporadic breast cancer. This study resulted in a number of manuscripts including first author papers in the Lancet and Human Molecular Genetics.
In addition, David was author on a number of breast cancer consortium papers including the landmark paper describing the cloning of the BRCA2 gene in Nature. In addition to his studies in breast cancer genetics, he formed a longstanding collaboration with Professor Irene Leigh at the Royal London Hospital, performing genetic studies on familial palmoplantar keratodermas, particularly the localization of a predisposition gene to both skin disease and oesophageal cancer.
After a short but successful Wellcome Trust postdoctoral in which time his team identified Connexin 26 as the main genetic cause of hearing loss, he joined SmithKline Beecham (now GlaxoSmithkline) where he used a bioinformatic approach to identify new molecular targets. From there he returned to academia and the Centre for Cutaneous Research as a Senior Lecturer to build an independent research team working on human skin genetics and keratinocyte biology.
David was made Professor of Human Molecular Genetics in September 2003. He is Deputy Director of Research at the Blizard Institute and board member of the European Society of Dermatological Research.
Morgan is Lead GI Histopathologist for St Mark's Hospital.
Morgan Moorghen trained in medicine at the Universities of St Andrews and Manchester. His postgraduate training was undertaken in the University department of pathology, Newcastle upon Tyne where he acquired an interest in gastrointestinal pathology and was also an active member of the Newcastle cell-kinetics research group.
Following the completion of his specialist training in histopathology and the submission of his MD thesis on colorectal neoplasia, he took up the post of Consultant Senior Lecturer in pathology at Bristol University in 1991 where he was lead GI histopathologist for 19 years. In Bristol he developed his clinical and research interests in colorectal cancer further, supervised several MSc and PhD students and contributed to numerous publications. During some of that time he also held the positions of clinical director of pathology and head of department of histopathology at the Bristol Royal Infirmary.
Currently he is training programme director in histopathology for North West London and also organises and teaches in the annual St Mark’s workshop in Gastrointestinal Histopathology. His main research interests include investigations into the role of obesity in development of colorectal cancer, mechanisms of NSAIDs in the prevention of colorectal cancer and the identification of prognostic factors in early colorectal cancer. He is also involved in a number of collaborative research projects with other members of the St Mark’s Academic Institute.
Sue is the Dean of St Mark's Academic Institution and Adjunct Professor of the Department of Surgery and Cancer at Imperial College.
Sue trained in medicine at Cambridge University and then St Thomas' Medical School in London. She completed her surgical training in the South West Thames Region, at St Mark's Hospital and at Mount Sinai Hospital in Toronto.
She then spent three years as a consultant at the Royal London Hospital before returning to St Mark's. During this time Sue set up a family cancer clinic to provide services for inherited or potentially inherited colorectal cancer in the North East London Cancer Network. Sue's practice covers most aspects of colorectal and anal surgery. Her main subspecialist area of expertise is in inherited colorectal cancer syndromes and she is the Director of the St Mark's Hospital Polyposis Registry.
Charlie is the Director of the National Bowel Research Centre and
Deputy Centre Lead for Trauma and Surgery at Barts and the London School of Medicine and Dentistry. He is the Administrative Chair of the grants committee.
Professor Knowles is Director of the NIHR Enteric Healthcare Technology Cooperative, Director of the National Bowel Research Centre and Surgical Specialty Lead for North Thames NIHR CRN.
He holds research positions in the European Society of Coloproctology and Association of Coloproctology of Great Britain and Ireland. He is Chair to UEG-led international working groups in anorectal physiology and GI neuromuscular diseases.
He serves as a member of the Rome IV committee for anorectal disorders and is on the global expert panel for Medtronic. He is a panel member for NIHR i4i and is on the editorial board of two journals. He has authored over 150 peer-reviewed publications as well as contributing several book chapters to major colorectal and general surgical texts.
He is also a trustee of Bowel & Cancer Research.
Sir Nick is the Centre Lead for the Centre for Tumour Biology at Barts Cancer Institute. He is the Awards Chair for the grants committee.
Sir Nick Chairs the grants committee. He is currently Warden of Barts and the London School of Medicine and Dentistry and he is Centre Lead for Tumour Biology at Barts Cancer Institute. His research interests include clonal evolution in bowel cancer and inflammation-associated cancer.
Sir Nick was knighted in 2006 for services to medicine.